Fredrik S.
- Country
- Norway
- Department
- Avdeling for blodsykdommer, Oslo myeloma center
Research Overview
- Phase 1/2 Study of TG01/QS-21 Vaccine in KRAS/NRAS Mutant High-Risk Smoldering or Active Multiple Myeloma with Measurable Disease Post-Treatment
- Efficacy and Safety of Etentamig and Daratumumab Versus Daratumumab and Combination Therapy in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma
- Phase 3 Randomized Study of Subcutaneous Daratumumab Versus Active Monitoring in High-Risk Smoldering Multiple Myeloma Patients
Data & Insights
Has run more than one trial at 22 of 98 partner sites.
Specializations
Multiple Myeloma Treatment Research
This investigator focuses on groundbreaking therapeutic approaches in multiple myeloma, with particular emphasis on novel drug combinations and treatment strategies. Their research encompasses both newly diagnosed cases and relapsed/refractory multiple myeloma.
- Novel therapeutic combinations
- Treatment optimization strategies
- Post-transplant maintenance therapy
Early Disease Intervention
The investigator specializes in studying interventions for high-risk smoldering multiple myeloma, exploring preventive strategies and early treatment approaches. Their work includes evaluation of innovative therapies for disease progression prevention.
- Early disease intervention protocols
- Risk assessment methodologies
- Disease progression monitoring
Therapeutic Innovation
Research initiatives include evaluation of immunotherapy approaches and novel drug delivery methods, with particular focus on subcutaneous versus intravenous administration of therapeutic agents and minimal residual disease assessment.
- Immunotherapy development
- Drug delivery optimization
- Treatment response assessment
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.